Working...

Working...

This value you provided is not a number. Please try again.

This value you provided is not an integer. Please try again.

The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again.

The value you provided must be within the suggested range

The value you provided is outside the suggested range

This value is admissible, but you may wish to double check it.

The value entered must be a time value in the following format HH:MM within the range 00:00-23:59 (e.g., 04:32 or 23:19).

This field must be a 5 or 9 digit U.S. ZIP Code (like 94043). Please re-enter it now.

This field must be a 10 digit U.S. phone number (like 415 555 1212). Please re-enter it now.

This field must be a valid email address (like joe@user.com). Please re-enter it now.

The value you provided could not be validated because it does not follow the expected format. Please try again.

Required format:

/^((0?[1-9])|([1-8][0-9])|(9[0-8]))[0-9]{3}$/

/^((29([-\/])02\3(\d{2}([13579][26]|[2468][048]|04|08)|(1600|2[048]00)))|((((0[1-9]|1\d|2[0-8])([-\/])(0[1-9]|1[012]))|((29|30)([-\/])(0[13-9]|1[012]))|(31([-\/])(0[13578]|1[02])))(\11|\15|\18)\d{4}))$/

/^((02([-\/])29\3(\d{2}([13579][26]|[2468][048]|04|08)|(1600|2[048]00)))|((((0[1-9]|1[012])([-\/])(0[1-9]|1\d|2[0-8]))|((0[13-9]|1[012])([-\/])(29|30))|((0[13578]|1[02])([-\/])31))(\11|\15|\19)\d{4}))$/

/^(((\d{2}([13579][26]|[2468][048]|04|08)|(1600|2[048]00))([-\/])02(\6)29)|(\d{4}([-\/])((0[1-9]|1[012])(\9)(0[1-9]|1\d|2[0-8])|((0[13-9]|1[012])(\9)(29|30))|((0[13578]|1[02])(\9)31))))$/

/^((29([-\/])02\3(\d{2}([13579][26]|[2468][048]|04|08)|(1600|2[048]00)))|((((0[1-9]|1\d|2[0-8])([-\/])(0[1-9]|1[012]))|((29|30)([-\/])(0[13-9]|1[012]))|(31([-\/])(0[13578]|1[02])))(\11|\15|\18)\d{4})) (\d|[0-1]\d|[2][0-3]):[0-5]\d$/

/^((02([-\/])29\3(\d{2}([13579][26]|[2468][048]|04|08)|(1600|2[048]00)))|((((0[1-9]|1[012])([-\/])(0[1-9]|1\d|2[0-8]))|((0[13-9]|1[012])([-\/])(29|30))|((0[13578]|1[02])([-\/])31))(\11|\15|\19)\d{4})) (\d|[0-1]\d|[2][0-3]):[0-5]\d$/

/^(((\d{2}([13579][26]|[2468][048]|04|08)|(1600|2[048]00))([-\/])02(\6)29)|(\d{4}([-\/])((0[1-9]|1[012])(\9)(0[1-9]|1\d|2[0-8])|((0[13-9]|1[012])(\9)(29|30))|((0[13578]|1[02])(\9)31)))) (\d|[0-1]\d|[2][0-3]):[0-5]\d$/

/^((29([-\/])02\3(\d{2}([13579][26]|[2468][048]|04|08)|(1600|2[048]00)))|((((0[1-9]|1\d|2[0-8])([-\/])(0[1-9]|1[012]))|((29|30)([-\/])(0[13-9]|1[012]))|(31([-\/])(0[13578]|1[02])))(\11|\15|\18)\d{4})) (\d|[0-1]\d|[2][0-3])(:[0-5]\d){2}$/

/^((02([-\/])29\3(\d{2}([13579][26]|[2468][048]|04|08)|(1600|2[048]00)))|((((0[1-9]|1[012])([-\/])(0[1-9]|1\d|2[0-8]))|((0[13-9]|1[012])([-\/])(29|30))|((0[13578]|1[02])([-\/])31))(\11|\15|\19)\d{4})) (\d|[0-1]\d|[2][0-3])(:[0-5]\d){2}$/

/^(((\d{2}([13579][26]|[2468][048]|04|08)|(1600|2[048]00))([-\/])02(\6)29)|(\d{4}([-\/])((0[1-9]|1[012])(\9)(0[1-9]|1\d|2[0-8])|((0[13-9]|1[012])(\9)(29|30))|((0[13578]|1[02])(\9)31)))) (\d|[0-1]\d|[2][0-3])(:[0-5]\d){2}$/

/^(?!\.)((?!.*\.{2})[a-zA-Z0-9\u0080-\u02AF\u0300-\u07FF\u0900-\u18AF\u1900-\u1A1F\u1B00-\u1B7F\u1D00-\u1FFF\u20D0-\u214F\u2C00-\u2DDF\u2F00-\u2FDF\u2FF0-\u2FFF\u3040-\u319F\u31C0-\uA4CF\uA700-\uA71F\uA800-\uA82F\uA840-\uA87F\uAC00-\uD7AF\uF900-\uFAFF!#$%&'*+\-/=?^_`{|}~\d]+)(\.[a-zA-Z0-9\u0080-\u02AF\u0300-\u07FF\u0900-\u18AF\u1900-\u1A1F\u1B00-\u1B7F\u1D00-\u1FFF\u20D0-\u214F\u2C00-\u2DDF\u2F00-\u2FDF\u2FF0-\u2FFF\u3040-\u319F\u31C0-\uA4CF\uA700-\uA71F\uA800-\uA82F\uA840-\uA87F\uAC00-\uD7AF\uF900-\uFAFF!#$%&'*+\-/=?^_`{|}~\d]+)*@(?!\.)([a-zA-Z0-9\u0080-\u02AF\u0300-\u07FF\u0900-\u18AF\u1900-\u1A1F\u1B00-\u1B7F\u1D00-\u1FFF\u20D0-\u214F\u2C00-\u2DDF\u2F00-\u2FDF\u2FF0-\u2FFF\u3040-\u319F\u31C0-\uA4CF\uA700-\uA71F\uA800-\uA82F\uA840-\uA87F\uAC00-\uD7AF\uF900-\uFAFF\-\.\d]+)((\.([a-zA-Z\u0080-\u02AF\u0300-\u07FF\u0900-\u18AF\u1900-\u1A1F\u1B00-\u1B7F\u1D00-\u1FFF\u20D0-\u214F\u2C00-\u2DDF\u2F00-\u2FDF\u2FF0-\u2FFF\u3040-\u319F\u31C0-\uA4CF\uA700-\uA71F\uA800-\uA82F\uA840-\uA87F\uAC00-\uD7AF\uF900-\uFAFF]){2,63})+)$/i

/^[-+]?\b\d+\b$/

/^[a-z]+$/i

/^\d{10}$/

/^[a-z0-9-_]+$/i

/^[-+]?[0-9]*\.?[0-9]+([eE][-+]?[0-9]+)?$/

/^-?\d+,\d$/

/^-?\d+\.\d$/

/^-?\d+,\d{2}$/

/^-?\d+\.\d{2}$/

/^-?\d+,\d{3}$/

/^-?\d+\.\d{3}$/

/^-?\d+,\d{4}$/

/^-?\d+\.\d{4}$/

/^[-+]?[0-9]*,?[0-9]+([eE][-+]?[0-9]+)?$/

/^(\(0[2-8]\)|0[2-8])\s*\d{4}\s*\d{4}$/

/^(?:\(?([2-9]0[1-9]|[2-9]1[02-9]|[2-9][2-9][0-9]|800|811)\)?)\s*(?:[.-]\s*)?([0-9]{3})\s*(?:[.-]\s*)?([0-9]{4})(?:\s*(?:#|x\.?|ext\.?|extension)\s*(\d+))?$/

/^((((\+44|0044)\s?\d{4}|\(?0\d{4}\)?)\s?\d{3}\s?\d{3})|(((\+44|0044)\s?\d{3}|\(?0\d{3}\)?)\s?\d{3}\s?\d{4})|(((\+44|0044)\s?\d{2}|\(?0\d{2}\)?)\s?\d{4}\s?\d{4}))(\s?\#(\d{4}|\d{3}))?$/

/^\d{4}$/

/^[ABCEGHJKLMNPRSTVXY]{1}\d{1}[A-Z]{1}\s*\d{1}[A-Z]{1}\d{1}$/i

/^(0[1-9]|[1-9]\d)\d{3}$/

/^\d{3}-\d\d-\d{4}$/

/^(\d|[01]\d|(2[0-3]))(:[0-5]\d){2}$/

/^([0-9]|[0-1][0-9]|[2][0-3]):([0-5][0-9])$/

/^[0-5]\d:[0-5]\d$/

/^[0-9]{4,9}$/

/^\d{5}(-\d{4})?$/

Delineating the molecular and clinical spectrum of epilepsy-dyskinesia syndromes in children (Epilepsy-Dyskinesia Spectrum Study)

You are invited to participate in a retrospective multicenter study: Delineating the Molecular and Clinical Spectrum of Epilepsy-Dyskinesia Syndromes in Children (The Epilepsy-Dyskinesia Spectrum Study).

Enrollment criteria: Any patient with pathogenic or likely-pathogenic variants in one of the genes below and at least one childhood-onset movement disorder.

AARS2	CSTB	GABRB2	KCNA2	NARS2	PIGP	SETBP1	SZT2
ALG13	DARS2	GABRB3	KCNB1	NHLRC1	PIGQ	SETD5	TARS2
AP3B2	DLAT	GABRG2	KCNC1	PCDH12	PIGS	SLC13A5	TBC1D24
AP4B1	DLD	GNAO1	KCNMA1	PCDH19	PLCB1	SLC1A2	TBL1WL1
AP4E1	DNM1	GRIA2	KCNQ2	PDE10A	POLG	SLC25A22	UBA5
AP4M1	EARS2	GRIA4	KCNQ3	PDE2	PRRT2	SLC2A1	UBE3A
AP4S1	EPG5	GRIN1	KCNT1	PDHA1	PURA	SMC1A	VAMP2
ARX	EPM2A	GRIN2A	LARS2	PDHB	RHOBTB2	SNX14	VARS2
ATP1A3	FARS2	GRIN2B	MECP2	PDHX	SCN1A	SPTAN1	WARS2
CACNA1A	FOXG1	GRIN2D	MEF2C	PDK3	SCN1B	ST3GAL3	WDR45
CACNA1E	FRRS1L	HARS2	MTND5	PDP1	SCN2A	STXBP1	WWOX
CACNA2D2	GABRA1	HNRNPU	MTTK	PIGA	SCN8A	SYNGAP1	YIF1B
CDKL5	GABRA2	IQSEC2	MTTL1	PIGN	SCN9A	SYNJ1	YWHAG

All contributing investigators will be recognized as collaborators on any publications that result from this study.

This study is approved by the Institutional Review Board at Boston Children's Hospital (IRB-P00044666). Investigators should make sure to adhere to their institution's policies for sharing de-identified information. If additional local IRB approval is required for sharing data, a copy of the IRB approval letter at Boston Children's Hospital can be provided.

You can save and return to an entry from the button at the bottom of the form, but each form is unique to each patient, so you will need to save the link to that specific form.

If you have any questions, please do not hesitate to contact us at movementdisorders@childrens.harvard.edu.

Loading...

Contributor

* must provide value

Contributor Email

* must provide value

Date

* must provide value

M-D-Y

Do you follow a patient with a diagnosis of a movement disorder with or without epilepsy due to pathogenic variants in any of the follow genes (1 choice per survey):

* must provide value

Affected Alleles?

* must provide value

Mono-allelic (1 allele mutated)

Bi-allelic (2 alleles mutated in trans)

Please enter the variant details

Variant - Allele 1 [DNA] (c.__________)

* must provide value

Variant - Allele 1 [protein] (p.__________)

Variant - Allele 2 [DNA] (c.__________)

* must provide value

Variant - Allele 2 [protein] (p.__________)

Inheritance

* must provide value

Diagnosis was made by

* must provide value

Array comparative genomic hybridization (aCGH) (also known as chromosomal microarray)

Single gene testing (Sanger sequencing)

Multigene Panel

Exome sequencing

Genome sequencing

Other

Information not available.

Other

Is this patient still alive?

* must provide value

Yes

No

Age at death (in years and months)

years months

Sex

* must provide value

Female

Male

Age at last evaluation (in years and months)

years months

Age at genetic diagnosis (in years and months)

years months

Age at first diagnosis of epilepsy

Age at first diagnosis of a movement disorder

Location of the patient (country)

* must provide value

Please select the most prominent movement disorder phenomenology:

* must provide value

Please describe the typical variation of the most prominent movement disorder

* must provide value

Diurnal fluctuation of the most prominent movement disorder?

* must provide value

Yes

No

Please select the second most prominent movement disorder phenomenology

* must provide value

Please describe the typical variation of the second most prominent movement disorder

Diurnal fluctuation of the second most prominent movement disorder?

Yes

No

Select all that apply upon examination at last follow up

Dystonia

* must provide value

Yes

No

Orofacial dystonia

* must provide value

Yes

No

Cervical dystonia

* must provide value

Yes

No

Truncal dystonia

* must provide value

Yes

No

Limb dystonia

* must provide value

Yes

No

History of status dystonicus

* must provide value

Yes

No

Oculogyric crises

* must provide value

Yes

No

Chorea

* must provide value

Yes

No

Athetosis

* must provide value

Yes

No

Ballism

* must provide value

Yes

No

Orofacial dyskinesia

* must provide value

Yes

No

Ataxia

* must provide value

Yes

No

Cerebellar ataxia

* must provide value

Yes

No

Truncal ataxia

* must provide value

Yes

No

Limb ataxia

* must provide value

Yes

No

Gait ataxia

* must provide value

Yes

No

Tremor

* must provide value

Yes

No

Rest tremor

* must provide value

Yes

No

Action tremor

* must provide value

Yes

No

Tremor of the head/chin

* must provide value

Yes

No

Tremor of the upper extremities

* must provide value

Yes

No

Tremor of the lower extremities

* must provide value

Yes

No

Myoclonus

* must provide value

Yes

No

Focal or segmental myoclonus

* must provide value

Yes

No

Generalized myoclonus

* must provide value

Yes

No

Eyelid myoclonus

* must provide value

Yes

No

Paroxysmal dyskinesia

* must provide value

Kinesigenic

Non-Kinesigenic

Exertion-induced

Mixed

Nocturnal

Fatigue

Illness/Fever

Other

None

Other

Bradykinesia

* must provide value

Yes

No

Hypomimia

* must provide value

Yes

No

Rigidity

* must provide value

Yes

No

Spasticity

* must provide value

Yes

No

Spasticity in legs

* must provide value

Yes

No

Spasticity in arms

* must provide value

Yes

No

Motor stereotypies

* must provide value

Yes

No

Motor tics

* must provide value

Yes

No

Vocal tics

* must provide value

Yes

No

Axial hypotonia

* must provide value

Yes

No

Severity of hypotonia

* must provide value

Head control achieved

* must provide value

Yes

No

Independent sitting achieved

* must provide value

Yes

No

Independent walking achieved

* must provide value

Yes

No

Age at independent walking achieved

years months

Level of ambulation at last visit

* must provide value

Level 0. Walking unrestricted.

Level I. Can walk indoors and outdoors and climb stairs without using hands for support. Can perform usual activities such as running and jumping. Has decreased speed, balance and coordination.

Level II. Has the ability to walk indoors and outdoors and climb stairs with a railing. Has difficulty with uneven surfaces, inclines or in crowds. Has only minimal ability to run or jump.

Level III. Walks with assistive mobility devices indoors and outdoors on level surfaces. May be able to climb stairs using a railing. May propel a manual wheelchair. May require assistance for long distances or uneven surfaces.

Level IV. Walking ability severely limited even with assistive devices. Uses wheelchairs most of the time and may propel their own power wheelchair. May participate in standing transfers.

Level V. Has physical impairments that restrict voluntary control of movement and the ability to maintain head and neck position against gravity. Is impaired in all areas of motor function. Cannot sit or stand independently, even with adaptive equipment. Cannot independently walk, though may be able to use powered mobility.

Age at walking aid dependence (years)

* must provide value

Age at wheelchair dependence (years)

* must provide value

History of developmental delay

* must provide value

Intellectual disability

* must provide value

Motor delay

* must provide value

Yes

No

Speech delay/impairment

* must provide value

Yes

No

Non-verbal

* must provide value

Yes

No

Dysarthria

* must provide value

Yes

No

Hypophonia

* must provide value

Yes

No

Developmental or cognitive regression

* must provide value

Yes

No

Behavioral dysregulation

* must provide value

Yes

No

Autistic features

* must provide value

Yes

No

Attention-deficit hyperactivity disorder

* must provide value

Yes

No

Self-injurious behaviors

* must provide value

Yes

No

Sleep disorders

* must provide value

Yes

No

Head circumference

* must provide value

Epilepsy

* must provide value

Yes

No

Type of seizures

* must provide value

Medically-refractory seizures (seizures despite 2 or more adequately dosed anti-seizure medications)

* must provide value

Yes

No

Developmental and epileptic encephalopathy (drug-resistant epilepsy and global developmental delay in early childhood)

* must provide value

Yes

No

Infantile spasms

* must provide value

Yes

No

Ohtahara syndrome

* must provide value

Yes

No

Lennox-Gastaut syndrome

* must provide value

Yes

No

Dravet syndrome

* must provide value

Yes

No

Epilepsy of infancy with migrating focal seizures

* must provide value

Yes

No

Current level of seizure control

* must provide value

Ocular/vision abnormalities

* must provide value

None

Strabismus

Nystagmus

Oculomotor dyspraxia

Tonic upgaze

Cortical visual impairment (CVI)

Gastrointestinal abnormalities

* must provide value

None

Dysphagia

G-tube dependence

Gastro-esophageal reflux

Severe constipation

Cerebral atrophy on head CT or brain MRI

* must provide value

Yes

No

Information not available

Cerebellar atrophy on head CT or brain MRI

* must provide value

Yes

No

Information not available

Brain stem atrophy on head CT or brain MRI

* must provide value

Yes

No

Information not available

Cerebellar hypoplasia on head CT or brain MRI

* must provide value

Yes

No

Information not available

Brain stem hypoplasia on head CT or brain MRI

* must provide value

Yes

No

Information not available

Presence of other developmental brain malformations on head CT or brain MRI

* must provide value

Yes

No

Information not available

Signal abnormalities in the basal ganglia on brain MRI

* must provide value

Yes

No

Information not available

White matter signal abnormalities on head CT or brain MRI

* must provide value

Yes

No

Information not available

Evidence of iron deposition on brain MRI

* must provide value

Yes

No

Information not available

Evidence of calcifications on head CT or brain MRI

* must provide value

Yes

No

Information not available

Additional findings on head CT or brain MRI

Is or was the patient taking any of the following medications (current & past)

* must provide value

Acetazolamide

ACTH

Amantadine

Aripiprazole

Baclofen

Benztropine

Botox (or equivalent) - i.m. injections

Brivaracetam

Cannabidiol or other cannabis preparation

Carbamazepine

Clobazam

Clonazepam

Clonidine

Dantrolene

Deu-tetrabenazine

Diazepam

Ethosuximide

Felbamate

Flunarizine

Gabapentin

Guanfacine

Haloperidol

Lacosamide

Lamotrigine

Levetiracetam

Levodopa / carbidopa

Lorazepam

Midazolam

Olanzapine

Oxcarbazepine

Perampanel

Phenobarbital

Phenytoin

Pimozide

Piracetam

Pramipexol

Prednisolone

Pregabalin

Primidone

Propranolol

Rasagiline

Risperidone

Rufinamide

Selegiline

Stiripentol

Sulthiame

Tetrabenazine

Tiagabine

Tizanidine

Topiramate

Triheptanoin

Trihexyphenidyl

Valbenazine

Valproate

Vigabatrin

Zonisamide

None

Has acetazolamide shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has ACTH shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has amantadine shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has aripiprazole shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has baclofen shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has benztropine shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has botox (or equivalent) - i.m. injections shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has brivaracetam shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has cannabidiol or other cannabis preparation shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has carbamazepine shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has clobazam shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has clonazepam shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has clonidine shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has dantrolene shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has deu-tetrabenazine shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has diazepam shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has ethosuximide shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has felbamate shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has flunarizine shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has gabapentin shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has guanfacine shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has haloperidol shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has lacosamide shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has lamotrigine shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has levetiracetam shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has levodopa/carbidopa shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has lorazepam shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has midazolam shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has olanzapine shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has oxcarbazepine shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has perampanel shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has phenobarbital shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has phenytoin shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has pimozide shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has piracetam shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has pramipexol shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has pregabalin shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has primidone shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has propranolol shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has rasagiline shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has risperidone shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has rufinamide shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has selegiline shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has stiripentol shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has sulthiame shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has tetrabenazine shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has tiagabine shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has tizanidine shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has topiramate shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has triheptanoin shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has trihexyphenidyl shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has valbenazine shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has valproate shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has vigabatrin shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has zonisamide shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Has prednisolone shown

Permanent benefit for the movement disorder

Transient benefit for the movement disorder

Permanent benefit for the epilepsy

Transient benefit for the epilepsy

Benefit for the movement disorder or epilepsy but also side effects

Benefit for the movement disorder and epilepsy but also side effects

No benefit

Dose limiting side-effects before a therapeutic dose could be reached

Worsening of movement disorder

Treatment effect unknown

Other past or present medications for seizures or movement disorders not listed above

Is/was the patient receiving treatment with a ketogenic diet?

* must provide value

Yes

No

Is the patient receiving deep brain stimulation

* must provide value

If so, what was the impact of DBS on the dystonia?

* must provide value

Is the patient receiving treatment with an intrathecal baclofen pump

* must provide value

Yes

No

Has this patient been previously reported in a peer-reviewed publication?

* must provide value

Yes

No

Please provide the PMID

* must provide value

You have selected an option that triggers this survey to end right now.

To save your responses and end the survey, click the 'End Survey' button below. If you have selected the wrong option by accident and/or wish to return to the survey, click the 'Return and Edit Response' button.